Current and emerging therapies for polycythemia vera

Lucia Masarova, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on current and emerging therapies for polycythemia vera (PV), highlighting clinical trials investigating these agents. Dr Masarova discusses the approval of ropeginterferon alfa-2b and the ECLIPSE PV trial (NCT05481151), before also covering the REVIVE and MAJIC-PV studies investigating rusfertide and ruxolitinib respectively (NCT04057040; ISRCTN61925716). This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.